SMC
VRTX icon

Smith, Moore & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

Smith, Moore & Co’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-455
Closed -$212K – 504
2024
Q3 		$212K Buy
+455
New +$219K 0.02% 438

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Smith, Moore & Co's VRTX Position: Q4 2024 in Review

Smith, Moore & Co sold out of Vertex Pharmaceuticals (VRTX) in Q4 2024, closing a stake of 455 shares — an estimated $212K sold.

Smith, Moore & Co first reported a position in VRTX in Q3 2024 and held it in 1 quarter. The position peaked at $212K in Q3 2024. 1,557 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

  • Smith, Moore & Co reported no remaining Vertex Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Smith, Moore & Co sold 455 Vertex Pharmaceuticals shares in Q4 2024, an estimated $212K.
  • Smith, Moore & Co first reported a position in Vertex Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Smith, Moore & Co's Vertex Pharmaceuticals position peaked at $212K in Q3 2024.
  • 1,557 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on Smith, Moore & Co's 13F filing for Q4 2024, filed 13 Feb 2025.